Cilostazol is associated with improved outcomes after peripheral endovascular interventions

Journal of Vascular Surgery

Volumn 59, Issue 6, 2014, Pages 1607-1614

  Warner, Courtney J ^a   Greaves, Spencer W ^b   Larson, Robin J ^b   Stone, David H ^a   Powell, Richard J ^a   Walsh, Daniel B ^a   Goodney, Philip P ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; TICLOPIDINE;

AMPUTATION; ANGIOPLASTY; ANTICOAGULANT THERAPY; ARTERIAL STENT; ARTERY OCCLUSION; ARTICLE; CARDIOVASCULAR RISK; CRITICAL LIMB ISCHEMIA; FOLLOW UP; HUMAN; IN-STENT RESTENOSIS; LIMB SALVAGE; META ANALYSIS; OVERALL SURVIVAL; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; REVASCULARIZATION; RISK REDUCTION; SURGICAL MORTALITY; SYSTEMATIC REVIEW;

ARTERIAL OCCLUSIVE DISEASES; ENDOVASCULAR PROCEDURES; FEMORAL ARTERY; GRAFT OCCLUSION, VASCULAR; GRAFT SURVIVAL; HUMANS; INCIDENCE; PLATELET AGGREGATION INHIBITORS; POPLITEAL ARTERY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TETRAZOLES; TREATMENT OUTCOME; WORLD HEALTH;

EID: 84900805629     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2013.11.096     Document Type: Article

References (24)

1. M. Schillinger, S. Sabeti, C. Loewe, P. Dick, J. Amighi, and W. Mlekusch et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery N Engl J Med 354 2006 1879 1888
2. A.K. Mitra, and D.K. Agrawal In stent restenosis: bane of the stent era J Clin Pathol 59 2006 232 239
3. J. Dorffler-Melly, M.M. Koopman, M.H. Prins, and H.R. Buller Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment Cochrane Database Syst Rev 1 2005 CD002071
4. L. Robertson, M.A. Ghouri, and F. Kovacs Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment Cochrane Database Syst Rev 8 2012 CD002071
5. S. Dindyal, and C. Kyriakides A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy Recent Pat Cardiovasc Drug Discov 4 2009 6 14
6. G.G. Biondi-Zoccai, M. Lotrionte, M. Anselmino, C. Moretti, P. Agostoni, and L. Testa et al. Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention Am Heart J 155 2008 1081 1089
7. J.S. Jang, H.Y. Jin, J.S. Seo, T.H. Yang, D.K. Kim, and D.S. Kim et al. A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation Cardiology 122 2012 133 143
8. O. Iida, S. Nanto, M. Uematsu, T. Morozumi, M. Kitakaze, and S. Nagata Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions J Vasc Surg 48 2008 144 149
9. I. Ikushima, K. Yonenaga, H. Iwakiri, H. Nagoshi, H. Kumagai, and Y. Yamashita A better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine Med Devices (Auckl) 4 2011 83 89
10. H. Ishii, Y. Kumada, T. Toriyama, T. Aoyama, H. Takahashi, and M. Tanaka et al. Effects of oral cilostazol 100 mg BID on long-term patency after percutaneous transluminal angioplasty in patients with femoropopliteal disease undergoing hemodialysis: a retrospective chart review in Japanese patients Clin Ther 32 2010 24 33
11. H. Ishii, Y. Kumada, T. Toriyama, T. Aoyama, H. Takahashi, and S. Yamada et al. Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease Clin J Am Soc Nephrol 3 2008 1034 1040
12. Y. Soga, O. Iida, K. Hirano, K. Suzuki, D. Kawasaki, and Y. Miyashita et al. Impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia J Vasc Surg 54 2011 1659 1667
13. Y. Soga, O. Iida, K. Hirano, K. Suzuki, H. Yokoi, and M. Nobuyoshi Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol Catheter Cardiovasc Interv 79 2012 541 548
14. Y. Soga, H. Yokoi, T. Kawasaki, H. Nakashima, M. Tsurugida, and Y. Hikichi et al. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication J Am Coll Cardiol 53 2009 48 53
15. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration; 2011. Available at: http://www.cochrane-handbook.org.
16. A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gotzsche, and J.P. Ioannidis et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Ann Intern Med 151 2009 W65 W94
17. M.S. Conte, P.J. Geraghty, A.W. Bradbury, N.D. Hevelone, S.R. Lipsitz, and G.L. Moneta et al. Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia J Vasc Surg 50 2009 1462-73.e1-3
18. J.P. Higgins, D.G. Altman, P.C. Gotzsche, P. Juni, D. Moher, and A.D. Oxman et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials BMJ 343 2011 d5928
19. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al, editors. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 3rd Symposium on Systematic Reviews: Beyond the Basics; 2000.
20. Review Manager (RevMan) 5.1. Copenhagen: The Nordic Cochrane Centre: Cochrane Collaboration; 2011.
21. Y. Soga, O. Iida, D. Kawasaki, K. Hirano, T. Yamaoka, and K. Suzuki Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia Eur J Vasc Endovasc Surg 44 2012 577 581
22. S. Dindyal, and C. Kyriakides Regarding "Impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia" J Vasc Surg 55 2012 891 author reply: 892-2
23. C.M. Pratt Analysis of the cilostazol safety database Am J Cardiol 87 2001 28D 33D
24. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg [serial on the Internet] 2008;47:330-336. Available at: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/993/ CN-00628993/frame.html.